石杉碱甲改善阿尔采末病相关线粒体功能损伤及潜在分子机制  

Ameliorative effects of huperzine A on Alzheimer' s disease associated mitochondrial dysfunction and its potential molecular mechanisms

作　　者：叶春艳[1] 章海燕[1] 

机构地区：[1]中国科学院上海药物研究所新药研究国家重点实验室,上海201203

出　　处：《中国新药与临床杂志》2012年第12期701-706,共6页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：阿尔采末病(AD)是一种常见的神经退行性疾病,目前临床上应用最广泛的AD治疗药物是乙酰胆碱酯酶抑制剂(AChEI)。石杉碱甲是我国自主研发的AChEI,近期研究显示除了胆碱酯酶抑制作用之外,石杉碱甲在大脑中动脉栓塞大鼠、APP/PS1转基因小鼠及β-淀粉样蛋白损伤的离体线粒体等多种模型中有显著的线粒体功能保护作用。本文对线粒体在AD发生发展中的作用和石杉碱甲对AD相关线粒体功能损伤的保护作用作一综述,并探讨其潜在的分子机制。Alzheimer＇ s disease （AD） is a common neurodegenerative disease, of which the most widely used therapeutic drug is acetylcholinesterase inhibitor （AChEI） . Huperzine A, an alkaloid developed by Chinese scientists, is a potent AChEI. Recent work reveals that besides the acetylcholinesterase inhibitoryeffect, huperzine A can also significantly benefit occlusion （MCAO） rat, APP/PS1 transgenic mic review summarizes the pivotal roles of mitochondri against AD associated mitochondrial dysfunction, above beneficial effects mitochondria in various models like e and - amyloid （A[5） injured isolal a in AD processing and the protective and also discusses the underlying mo middle cerebral artery ted mitochondria. This effects of huperzine A ,lecular mechanisms of

关 键 词：阿尔茨海默病 线粒体 石杉碱甲 胆碱酯酶抑制剂 

分 类 号：R971[医药卫生—药品] R965[医药卫生—药学]